Lymphedema Diagnostics Market Size was valued at USD 0.02 Billion in 2022. The Lymphedema Diagnostics market industry is projected to grow from USD 0.021 Billion in 2023 to USD 0.038 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2023 - 2032).Increased cases of chronic diseases like cancer and a large number of diagnostic procedures performed in hospitals are the key market drivers enhancing market growth.Â
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Market CAGR for lymphedema diagnostics is being driven by the rising cases of chronic diseases. The rising incidents of chronic diseases like cancer and lymphedema, with the increasing emphasis on quality of healthcare, are the main factors leading to the growth of the lymphedema diagnostics market during the forecast period. The rise in investment and the innovation of new models of diagnosis and a growing number of emerging countries are also boosting the market. There is increasing advancement in technology in diagnostic imaging modalities and investment.
Lymphedema is a long-lasting condition in which extra fluid gets collected in the tissues leading to swelling. The main reason for lymphedema is the genetic mutations in genes that are the reason for the development of the lymphatic system. Secondly, the causes like cancer, infection, radiation therapy, and inflammatory conditions lead to lymphedema. It is also known as lymphatic obstruction, which mainly affects arms and legs, and some patients even witness swelling in the head, chest, and genitals also. At present, the foundation of the majority of lymphedema risk models is comprised of cancer and treatment risk. The technological advancement offers improved diagnostic solutions; for instance, Bioimpedance Spectroscopy (BIS) is scalable and simple to integrate into the workflows, which is the tracking and addressing lymphedema future. BIS helps in detecting at the earliest stage to permit therapies that can largely enhance the enhancement to avoid cancer-related lymphedema for at-risk individuals. A large amount of investment, grants, and funds by the public-private organization and the government are anticipated to generate profitable opportunities for the market. Thus, driving the Lymphedema Diagnostics market revenue.
There are different factors affecting the growth of the market, like the limited supply of helium and the rising adoption of refurbished diagnostic imaging systems. Further, the high expenses related to diagnostic equipment and the absence of adequate reimbursements are affecting the growth of the market. For instance, women have high expenses related to breast cancer and lymphedema. The main setback of Magnetic Resonance Imaging (MRI) is the high-cost equipment and high level of technical expertise required to utilize the tools and the results are interpreted. The absence of suitable, clinically authorized lymphatic-specific MRI tracers limits the effectiveness of these imaging methods, thus restricting the market revenue growth.
The Lymphedema Diagnostics market segmentation, based on type, includes Lymphoscintigraphy, Magnetic Resonance Imaging, Computed Tomography, Ultrasound Imaging, and Others. The lymphoscintigraphy segment dominates the market, accounting for the largest market share as they help to identify molecular activity and has the capability to detect disease at the early stage. It has a noninvasive nature is another reason boosting the market growth; when compared to other severe surgery, it allows the minimum invasive procedure to be performed that has fewer side effects and minimum morbidity rate, which in turn boosts the market growth globally.
The Lymphedema Diagnostics market segmentation, based on end users, includes Hospitals, Diagnostic Centers, Inflammatory Diseases, and Others. The hospitals segment dominates the market for a considerably large revenue share due to the rising number of the population looking up to hospitals for performing diagnostic procedures. The availability of qualified lymphedema therapists and physical therapists assists the patients in recovering balance and reclaim the charge of their life with the utilization of specialized message methods and knowledge of modern treatment alternatives. The increasing launch of new centers for lymphedema care and the adoption of sophisticated equipment to help patients with their diagnosis and treatment are boosting the growth of the market.
Figure 1: Lymphedema Diagnostics Market, by Distribution Channel, 2022 & 2032 (USD Billion)Â
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Lymphedema Diagnostics market is due to the rising utilization of technologically advanced diagnostic imaging technology and improved insurance coverage policies. The increasing number of lymphedema cases in this region. The highest contributor to the lymphedema diagnostics market is the US in the North American region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Lymphedema Diagnostics MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Lymphedema Diagnostics market accounts for the second-largest market share due to the increased investment and R&D for developing innovative solutions for the early detection of diseases. Further, the German Lymphedema Diagnostics market held the largest market share, and the UK Lymphedema Diagnostics market was the rapid-growing market in the European region.
The Asia-Pacific Lymphedema Diagnostics Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because of the rising prevalence of cancer and kidney diseases, improved healthcare infrastructure, and rising R&D for inventing innovative diagnostic systems. Moreover, China’s Lymphedema Diagnostics market held the largest market share, and the Indian Lymphedema Diagnostics market was the rapid-growing market in the Asia-Pacific region.
Lymphedema Diagnostics Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to spread their product lines, which will help the Lymphedema Diagnostics market grow even more. Market participants are also undertaking a various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Lymphedema Diagnostics industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Lymphedema Diagnostics industry to benefit clients and increase the market sector. In recent years, the Lymphedema Diagnostics industry has offered some of the most significant advantages to medicine. Major players in the Lymphedema Diagnostics market, including Siemens Healthcare GmbH, Hitachi Ltd, Canon Inc, Shimadzu Corporation, Shanghai United Imaging Healthcare Co. Ltd, Stryker Corporation, Fluoptics, AIROS Medical, Mindray Medical International Ltd, ImpediMed Ltd, General Electric Company, and others, are attempting to increase market demand by investing in research and development operations.
ImpediMed is a medical technology company founded and headquartered in Brisbane, Australia, with US and European operations. It is a company that utilizes bio-impedance spectroscopy (BIS) technology to generate powerful data to increase patient health. ImpedMed uses bioimpedance in the noninvasive clinical assessment and monitoring of fluid status. The product portfolio consists of medical devices that help oncologists, surgeons, therapists, and radiation oncologists in the clinical assessment of the patient for the potential onset of secondary lymphoedema. In June 2020, an agreement was signed by an Australian manufacturer of medical devices, ImpediMed, with the US Oncology Network. Lymphedema can be diagnosed at an early stage with a bioimpedance spectroscopy instrument by recognizing a rise in extracellular fluid in a patient and also analyzing the fluid status and tissue composition.
AIROS Medical was established in 2016 outside of Philadelphia, Pennsylvania, by medical device experts in Durable Medical Equipment (DME) for decades. The company is a technology manufacturer specializing in compression therapy products for treating cancer-related lymphedema and venous complications. The company creates medical devices that enhance the quality of patient's life battling chronic diseases. The product line includes AIRO6 and AIRO8 Sequential Compression Devices. In January 2020, a new AIROS 8 Sequential Compression Therapy device and garment systems were given the approval of FDA 510(K).
Key Companies in the Lymphedema Diagnostics market include
Siemens Healthcare GmbH
Hitachi Ltd
Canon Inc
Shimadzu Corporation
Shanghai United Imaging Healthcare Co. Ltd
Stryker Corporation
Fluoptics
AIROS Medical
Mindray Medical International Ltd
ImpediMed Ltd
General Electric Company
Lymphedema Diagnostics Industry Developments
December 2022:The Lymphedema Treatment Act, a federal law, was passed and will become effective in January 2024. It aims to improve Medicare insurance coverage for the compression devices that are important for lymphedema treatment and are crucial medically and doctor-prescribed.
February 2022:The Cancer Prevention and Research Institute of Texas(CPRIT) announced 74 new grants for cancer research and prevention, totaling over USD 112,768,740. The projects accepted consists of 65 grants for research in academics, for preventive, seven grant, and two grants for the development and research of products given to 16 organization and businesses throughout the state. This aims to increase access to clinical trials and foster cutting-edge cancer research.
July 2021:Sakra World Hospital, on the occasion of World Plastic Surgery Day, officially launched a Comprehensive Lymphedema Vare Center with the aim to provide patients suffering from lymphedema comprehensive.
Lymphoscintigraphy
Magnetic Resonance Imaging
Computed Tomography
Ultrasound Imaging
Others
Hospitals
Diagnostic Centers
Inflammatory Diseases
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.02 Billion |
| Market Size 2023 | USD 0.021 Billion |
| Market Size 2032 | USD 0.038 Billion |
| Compound Annual Growth Rate (CAGR) | 7.50% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Technology, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Siemens Healthcare GmbH, Hitachi Ltd, Canon Inc, Shimadzu Corporation, Shanghai United Imaging Healthcare Co. Ltd, Stryker Corporation, Fluoptics, AIROS Medical, Mindray Medical International Ltd, ImpediMed Ltd, General Electric Company  |
| Key Market Opportunities | Increased technological advancements in the diagnostic fields. |
| Key Market Dynamics | Increased prevalence of chronic diseases and the increased diagnosis taking place in hospitals. |
Lymphedema Diagnostics Market Highlights:
Frequently Asked Questions (FAQ) :
The Lymphedema Diagnostics market size was valued at USD 0.02 Billion in 2022.
The market is foreseen to grow at a CAGR of 7.50% during the forecast period, 2023-2032.
North America had largest share of the market
The key players in market are Siemens Healthcare GmbH, Hitachi Ltd, Canon Inc, Shimadzu Corporation, Shanghai United Imaging Healthcare Co. Ltd, Stryker Corporation, Fluoptics, AIROS Medical, Mindray Medical International Ltd, ImpediMed Ltd, and General Electric Company.
The lymphoscintigraphy category dominated the market in 2022.
The hospital had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
